Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Last trade$26.19
Day change-$0.78 (-2.89%)
Day range$25.83 – $30.53
Volume768,875
Market cap$1.95B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.95B
Price / earnings
—
Price / book
5.85×
Price / sales
189.73×
EV / sales
191.69×
EV / EBITDA
-4.62×
Profitability
Earnings per share
-$5.76
Return on assets
-89.43%
Return on equity
-125.01%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.23×
Current ratio
7.91×
Quick ratio
7.78×
Cash ratio
0.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$376.05M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VERA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$10.28M
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$3.3M
$0
$0
$0
$0
$0
$0
$0
Gross profit
$6.98M
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$61.43M
$52.41M
$39.12M
$34.9M
$27.46M
$21.95M
$15.92M
$15.57M
Research and development
$41.25M
$60.08M
$86.01M
$59.31M
$56.47M
$58.2M
$41.28M
$33.35M
Total operating expenses
$102.68M
$112.49M
$125.13M
$94.21M
$83.93M
$80.14M
$57.19M
$48.91M
Operating income
-$95.7M
-$112.49M
-$125.13M
-$94.21M
-$83.93M
-$80.14M
-$57.19M
-$48.91M
Interest expense
-$1.87M
-$1.85M
-$1.82M
-$1.9M
-$1.96M
-$1.87M
-$1.79M
-$1.87M
Income before taxes
-$93.71M
-$109.72M
-$121.97M
-$91.1M
-$80.29M
-$76.66M
-$51.43M
-$43.42M
Income taxes
$0
$0
$0
$1K
$0
$0
$0
$1K
Net income
-$93.71M
-$109.72M
-$121.97M
-$91.1M
-$80.29M
-$76.66M
-$51.43M
-$43.43M
Net income attributable to common shareholders
-$93.71M
-$109.72M
-$121.97M
-$91.1M
-$80.29M
-$76.66M
-$51.43M
-$43.43M
EBITDA
-$94.88M
-$112.36M
-$124.99M
-$94.07M
-$83.8M
-$80.02M
-$57.11M
-$48.86M
Basic earnings per share
-$1.30
-$1.52
-$1.69
-$1.39
-$1.26
-$1.20
-$0.81
-$0.72
Diluted earnings per share
-$1.30
-$1.52
-$1.69
-$1.39
-$1.26
-$1.20
-$0.81
-$0.72
Recent news
Company coverage with links to the original publishers.
Vera Therapeutics announced that William Turner, current Chief Regulatory Officer, will retire and transition to Strategic Advisor role in Q3 2026. Nancy Boman, M.D., Ph.D., with over 25 years of regulatory affairs experience, will succeed him. The transition follows the recent accelerated FDA approval of TRUTAKNA (atacicept-vymj), the company's first therapy for IgA nephropathy.
Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics (VERA) during Q1 2026, valued at approximately $18.1 million. The position, which represented 2.0% of the fund's assets in the prior quarter, was fully exited. Despite the sale, Vera Therapeutics stock has surged 81.4% over the past year and outperformed the S&P 500 by 55 percentage points.
The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.
The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.
Deerfield Management Company increased its stake in Vera Therapeutics by 418,538 shares during Q4 2025, bringing its total position to $205.58 million (2.6% of fund AUM). Vera's stock has surged 50% over the past year as its lead drug candidate atacicept approaches an FDA decision on July 7, 2026, for treating IgA nephropathy. The company has sufficient cash reserves to fund operations through a potential approval and U.S. launch.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.